HC Wainwright Issues Optimistic Forecast for ATXS Earnings

Key Points

• HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Astria Therapeutics from ($0.69) to ($0.66), maintaining a "Buy" rating and a price target of $16.00.
• Other analysts have also shown optimism, with JMP Securities increasing their price target from $25.00 to $26.00 and Cantor Fitzgerald setting a target at $47.00.
• Astria Therapeutics recently reported an EPS of ($0.57), exceeding consensus estimates, while the stock has a current average target price of $29.00 among analysts.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Investment analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of Astria Therapeutics in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn ($0.66) per share for the quarter, up from their prior estimate of ($0.69). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Astria Therapeutics' Q4 2025 earnings at ($0.71) EPS and FY2025 earnings at ($2.53) EPS.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.04.

A number of other research analysts have also commented on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $47.00 price objective on shares of Astria Therapeutics in a report on Wednesday, May 14th. Citigroup restated an "outperform" rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Finally, JMP Securities raised their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $29.00.

Astria Therapeutics Stock Performance

Shares of NASDAQ ATXS traded up $0.01 during mid-day trading on Friday, reaching $6.31. 199,102 shares of the company traded hands, compared to its average volume of 358,089. The stock has a market cap of $356.14 million, a PE ratio of -3.14 and a beta of 0.48. The company's fifty day moving average is $6.26 and its two-hundred day moving average is $5.73. Astria Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $12.92.

Institutional Trading of Astria Therapeutics

A number of hedge funds have recently modified their holdings of ATXS. JPMorgan Chase & Co. lifted its position in shares of Astria Therapeutics by 39.6% in the 4th quarter. JPMorgan Chase & Co. now owns 54,664 shares of the biotechnology company's stock worth $489,000 after acquiring an additional 15,520 shares during the period. Wells Fargo & Company MN raised its position in Astria Therapeutics by 47.3% in the 4th quarter. Wells Fargo & Company MN now owns 23,569 shares of the biotechnology company's stock valued at $211,000 after purchasing an additional 7,563 shares during the last quarter. Legal & General Group Plc raised its position in Astria Therapeutics by 7.6% in the 4th quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 2,222 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Astria Therapeutics during the fourth quarter valued at $707,000. Finally, Barclays PLC lifted its position in Astria Therapeutics by 5.6% during the 4th quarter. Barclays PLC now owns 97,820 shares of the biotechnology company's stock valued at $875,000 after purchasing an additional 5,169 shares during the period. Institutional investors own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.